What is the difference between Glasdegib and Venetoclax? Which one is better?

Glasdegib and venetoclax are both drugs used to treat specific types of leukemia, but they have some differences in pharmacology, treatment indications, side effects, and patient response. Both of these drugs and their characteristics are discussed in detail below.

1. Pharmacology and mechanism:

Glasdegib (Glasdegib): Glasdegib is an inhibitor of the Hedgehog signaling pathway, acting on a protein called Smoothened that is abnormally active in some AML patients. By inhibiting the Hedgehog signaling pathway, Glasgib slows the growth and proliferation of AML cells.

Venetoclax (Venetoclax): Venetoclax is an inhibitor of BCL-2 (BCL-2) and its mechanism of action is related to apoptosis (programmed cell death). Apoptosis is part of the body's natural regulation of the cell life cycle. Venetoclax promotes leukemia cells to enter an apoptotic state by inhibiting the BCL-2 protein.

2. Treatment indications:

Glassgibb: Mainly used to treat newly discovered or refractory AML (acute myeloid leukemia).

Veneclat: Originally indicated for the treatment of chronic lymphocytic leukemia (CLL) and AML associated with defects in chromosome 17. Later, venetoclax was also approved for the treatment of certain subtypes of AML, especially those with mutations in the TP53 gene.

3. Side effects:

Grasgib: Common side effects of Glasgib include nausea, vomiting, diarrhea, fatigue, headache, etc. In addition, it may cause bone marrow suppression, making patients susceptible to infection and bleeding.

Veneclar: Common side effects of Venetacla include nausea, vomiting, diarrhea, fatigue, fever, etc. In some cases, venetoclax may cause severe cytolytic syndrome (TLS), requiring special monitoring and management.

4. Patient response and efficacy:

Grasgib: Glassygib is often used as part ofAML's treatment regimen to help control the condition. However, patient responses vary from person to person, and treatment results may vary based on a variety of factors.

Veneclat: Venetoclax has shown significant efficacy in patients with certain subtypes ofAML. Research suggests that venetoclax may be more effective than other treatments in patients with AML who have mutations in the TP53 gene.

5. Selection and treatment decisions:

TreatmentAML is a complex process that usually requires the most appropriate treatment plan based on the patient's specific situation and pathological analysis. Treatment selection usually considers the following factors:

Patient’s age and health status;

AMLSubtypes and molecular genetic characteristics;

Whether there are specific gene mutations, such asTP53;

History and response to other treatments.

In some cases, venetoclax and venetoclax may be used together to enhance the effectiveness of treatment. Treatment decisions should be made by a professional medical team based on the latest research and the patient's specific circumstances.

In summary, venetoclax and venetoclax are drugs used to treat different types ofAML, which differ in their mechanisms of action, indications, side effects, and patient responses. Which drug is better depends on the patient's specific situation, as well as the doctor's recommendations and treatment plan. Ultimately, treatment decisions should be made by medical professionals based on the patient's specific circumstances. If you or someone you know has leukemia or a similar disease, be sure to talk to your doctor for personalized treatment recommendations.

Glassgib is not yet available in the country, so it cannot be included in medical insurance. Patients cannot purchase it domestically and need to purchase Glassgib through overseas channels. In foreign countries, only Pfizer's original drug is available, and the price is high. The European version of the original drug is about 160,000 yuan.

Veneclar is already on the market in China, but the price is relatively high, so patients can buy it domestically. Venekra has been included in the medical insurance directory in March 2023. Since it has just been included in the medical insurance, you need to consult the local hospital pharmacy or the medical insurance bureau for specific policies. The current domestic price of Venekra is about 5,000 yuan for 100mg*14 tablets. The price is very high and difficult for ordinary families to accept. Overseas Venexacla includes original drugs and generic drugs. The price of original drugs is also relatively high, while the generic drugs are relatively cheap. For example, the price of Bangladeshi version of Verenaclat generic drug specifications100mg*120 tablets is about 4,000 to 5,000 yuan, and the price of generic drugs in Laos is about 4,000 to 5,000 yuan. The price of generic drugs is relatively much cheaper, and the drug ingredients are the same as the original drug.